Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H2 2017 Summary Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Retinoic acid receptor beta (RARB) is a nuclear receptor that is encoded by the RARB gene. RARB bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for skeletal growth, matrix homeostasis and growth plate functions. Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 1, 4 and 1 respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Immunology, Respiratory, Hematological Disorders, Metabolic Disorders, Oncology and Ophthalmology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Psoriasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Breast Cancer, Erythema Multiforme, Hormone Sensitive Breast Cancer, Hyperlipidemia, Inflammatory Bowel Disease, Myelodysplastic Syndrome, Neutropenia, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Retinopathy Of Prematurity and Type 2 Diabetes. The latest report Retinoic Acid Receptor Beta - Pipeline Review, H2 2017, outlays comprehensive information on the Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - The report reviews Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics and enlists all their major and minor projects - The report assesses Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Overview 7 Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics Assessment 14 Assessment by Mechanism of Action 14 Assessment by Route of Administration 15 Assessment by Molecule Type 17 Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Companies Involved in Therapeutics Development 19 3SBio Inc 19 Lee's Pharmaceutical Holdings Ltd 19 Phosphagenics Ltd 20 Promius Pharma LLC 20 Sol-Gel Technologies Ltd 20 Valeant Pharmaceuticals International Inc 21 Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Drug Profiles 22 (adapalene + clindamycin hydrochloride) - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 (benzoyl peroxide + tretinoin) - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 (clindamycin phosphate + tretinoin) - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 AC-261066 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 adapalene + benzoyl peroxide + clindamycin phosphate - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 alitretinoin - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 SBD-073 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 tamibarotene - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 tazarotene - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 tazoretene - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 TPX-6001 + tretinoin - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 tretinoin - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 tretinoin - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 vitamin A palmitate - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 vitamin A palmitate - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Dormant Products 45 Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Discontinued Products 46 Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Product Development Milestones 47 Featured News & Press Releases 47 Aug 31, 2017: Syros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 Congress 47 Aug 21, 2017: Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML 47 Jul 21, 2017: Syros Publishes Foundational Data Supporting Ongoing Phase 2 Clinical Trial of SY-1425 for Genomically Defined AML and MDS Patients 48 Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris 49 Jun 23, 2017: Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARa Agonist, in Genomically Defined AML and MDS Patients 50 May 18, 2017: Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients 51 May 08, 2017: Syros Presents New Insights on Mechanism of Action of SY-1425, Its First-in-Class Selective RARa Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference 51 May 04, 2017: Syros Reveals Discovery of Novel Drug Targets for Triple Negative Breast Cancer 52 May 01, 2017: Syros Participates in International Symposium to Support MDS Foundation's Efforts to Raise Awareness of Novel Therapies in Development for MDS 53 Apr 18, 2017: Syros to Present on SY-1425, Its First-in-Class Selective RARa Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference 54 Apr 04, 2017: Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RARa Agonist, for Genomically Defined AML and MDS Patients 54 Mar 01, 2017: Syros to Present New Data on SY-1425 at Upcoming AACR Annual Meeting 56 Jan 09, 2017: Syros Pharma Outlines 2017 Strategic Goals, Provides Update On SY-1425 57 Dec 10, 2016: Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Proliferative Effects of its First-in-Class Selective RARa Agonist in Genomically Defined Subsets of Breast Cancer 58 Dec 05, 2016: Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-in-Class Selective RARa Agonist for Genomically Defined Subsets of AML and MDS Patients 59 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indication, H2 2017 10 Number of Products under Development by Companies, H2 2017 11 Products under Development by Companies, H2 2017 12 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13 Number of Products by Stage and Mechanism of Actions, H2 2017 14 Number of Products by Stage and Route of Administration, H2 2017 16 Number of Products by Stage and Molecule Type, H2 2017 18 Pipeline by 3SBio Inc, H2 2017 19 Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017 19 Pipeline by Phosphagenics Ltd, H2 2017 20 Pipeline by Promius Pharma LLC, H2 2017 20 Pipeline by Sol-Gel Technologies Ltd, H2 2017 21 Pipeline by Valeant Pharmaceuticals International Inc, H2 2017 21 Dormant Projects, H2 2017 45 Discontinued Products, H2 2017 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
